| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a9bf8f8527cfdd7e1b25a4c8f3cca470 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6913
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2011-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00d06a176c03c99a1f63ca4740aa6c76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c68bae2005178c93405acb62baf88d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04baa8013d271e66309dc160bc01283b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a679e30bb9b61833c023c3bbcea341d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8fa4cda3f1a3ca18300671e5e34eff8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5295656a6f45a35aa177a40bcc414d79 |
| publicationDate |
2014-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2013006430-A |
| titleOfInvention |
DOSAGE AND ADMINISTRATION TO PREVENT CARDIOTOXICITY IN THE TREATMENT WITH ERBB2-FOCALIZED IMMUNOLIPOSOMES UNDERSTANDING ANTHRACICLINE CHEMOTHERAPEUTIC AGENTS. |
| abstract |
Methods for determining the dose of immunoliposomes containing HER2-focused anthracycline are described as methods for treating cancer patients with HER2-positive tumors using doses thus determined. After administration, the doses share the low cardiotoxicity profile of standard doses of liposomes containing non-immunoliposomal anthracycline (non-focused). |
| priorityDate |
2010-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |